A Scottish team that devised ground-breaking technology to create Covid tests at the height of the pandemic is to turn its focus to a range of other diseases.
Vertebrate Antibodies Limited (VAL) is linking up with US biotech giant Innova Medical Group (IMG) to adapt its technology to develop tests for a range of diseases including diabetes and Lyme Disease.
During the pandemic VAL used its technologies to develop antibody Covid tests as part of the rapid response research programme.
The University of Aberdeen spin-out secured the investment with IMG, a leading specialist in innovative solutions for rapid screening and diagnosis of diseases, to form a new holding company called EpitogenX.
The new venture will focus on the development of these technologies to reach industrial maturity for widespread distribution.
READ MORE: 'Game-changing' tests developed
EpitoPredikt, an AI-driven system, was designed to identify specific elements, or “hot spots”, of the Covid virus that would trigger the body’s immune response.
It will now be adapted to do the same for specific diseases. EpitoGen is described as a biological platform “scaffold”, developed to combine and display molecular elements as they would appear naturally in the pathogen or virus.
The firm said the approach enhances the test’s performance, improves sensitivity and, as was vital during the pandemic, is flexible to incorporate new strains and variants into the tests.
The company also said that the immediate objective for EpitogenX is to develop lab-based and point-of-care diagnostic tests for Lyme disease and diabetes, both of which “are notoriously difficult to diagnose early enough to enable timely intervention”.
READ MORE: Health: Five things to do now to reduce your risk
The new tests will be cheaper and "most importantly", have greater overall accuracy than currently available tests, it is claimed.
The long-term vision is to produce a portfolio of diagnostic products to detect autoimmune disorders and infectious diseases.
It said that fine-tuning of the technology could result in wider applications including vaccines and safer therapeutics for a variety of diseases.
Dr Abdo Alnabulsi, co-founder and chief executive of VAL, said its core technologies are “poised to transform” the diagnostic, vaccine, and therapeutic fields.
READ MORE: Call for more detailed sampling and mapping of Scotland's ticks
“Our platforms provide superior products and services compared to current alternatives, with unmatched accuracy, flexibility, and adaptability, all while remaining affordable and cost-effective," Dr Alnabulsi said. “This ensures that the benefits of our technologies are available to the NHS, low- and middle-income countries, and even the less-funded veterinary sector."
VAL spun out from the University of Aberdeen in 2011.
Dr Alnabulsi added: "From the start, we set out to revolutionise the research and clinical sectors with innovative technologies.
“We're thrilled to have found a partner in IMG who shares our vision and values and is equally committed to developing transformative products."
"I'm confident that this partnership will accomplish great things, and that our technology and products will make a global impact."
Professor Mirela Delibegovic, of the University of Aberdeen, who worked alongside VAL to develop the Covid test, said: “This investment into VAL is testament to the innovative and pioneering technology that has come out of the team. The potential for this technology is boundless and I look forward to seeing it used clinically in the future.”
Tiehui Wang, co-founder of VAL, said: “The first part of our journey has been full of challenges, but we successfully achieved what we set out to do. Now in the second leg, we will work closely with the IMG team to roll out the next-generation tests and clinical products.”
Ann Lewendon, also of the university, said: “The VAL team, now EpitoGenX, have always been visionaries, working to create disruptive platforms. I am glad to have been a part of their success story and witness their hard work come to fruition.”
Dr Robbin Xu, director of EpitogenX and scientific advisor at IMG, said: "IMG is proud of working with EpitogenX.
"Their innovative technology and the dedicated team have us confident in their ability to make a breakthrough in the near future."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereLast Updated:
Report this comment Cancel